Ensysce Biosciences (NASDAQ:ENSC) reported quarterly losses of $(0.79) per share which beat the analyst consensus estimate of $(1.18) by 33.05 percent. This is a 76.06 percent increase over losses of $(3.30) per share from the same period last year. The company reported quarterly sales of $1.371 million which beat the analyst consensus estimate of $650.000 thousand by 110.92 percent. This is a 654.14 percent increase over sales of $181.797 thousand the same period last year.